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Abstract 
Exploitation of photosensitisers as payloads for antibody-based anti-cancer therapeutics offers a novel 
alternative to the small pool of commonly-utilised cytotoxins. However, existing bioconjugation 
methodologies are incompatible with the requirement of increased antibody loading without 
compromising antibody function, stability or homogeneity. Herein, we describe the first application of 
dendritic multiplier groups to allow the loading of more than 4 porphyrins to a full IgG antibody in a 
site-specific and highly homogeneous manner. Photophysical evaluation of UV-visible absorbance 
and singlet oxygen quantum yields highlighted porphyrin-dendron 14 as the best candidate for 
bioconjugation; with subsequent bioconjugation producing a HER2-targeted therapeutic with average 
loading ratios of 15.4:1. In vitro evaluation of conjugate 18 demonstrated a nanomolar photocytotoxic 
effect in a target cell line, which overexpresses HER2, with no observed photocytotoxicity at the same 
concentration in a control cell line which expresses native HER2 levels, or in the absence of 
irradiation with visible light.  
Introduction 
The field of antibody-drug conjugates (ADCs) has experienced an explosion of research interest in 
recent years, with three clinically-approved drugs (Adcetris®, Kadyla® and Besponsa®) and over 60 
other ADCs currently undergoing clinical trials1. Despite this, the variety of payloads utilised is 
limited, with over two thirds of ADCs exploiting just two classes of cytotoxic agents; auristatins and 
maytansinoids2. One potential avenue to increase payload diversity lies in the field of 
photoimmunotherapeutic agents; tumour-associating antibodies loaded with photosensitisers. The 
exploitation of photosensitisers in photodynamic therapy (PDT) offers a completely novel mechanism 
of action; these drugs exhibit cytotoxic action only under irradiation with visible light, producing 
reactive oxygen species, most notably singlet oxygen, and resulting in a secondary cytotoxic action 
Although many examples of photoimmunotherapeutic agents exist3, their utility is limited by the 
bioconjugation methodologies used. For targeted PDT, conjugation to antibodies is typically achieved 
through lysine modification, however lysine modification is suboptimal as it generates heterogeneous 
products, which can result in batch-to-batch variability and poor pharmacokinetics. Cysteine 
modification, following inter-chain disulfide reduction is another viable strategy, however this results 
in the permanent loss of structural disulfide bonds, which may reduce the stability of the antibody 
conjugate in vivo. Moreover, cysteine modification is often carried out by reaction with classical 
maleimide compounds. Whilst this reaction is reliable, it has been widely reported (and proven in 
various guises) that the formed succinimide conjugate is unstable in serum, due to the propensity of 
this motif to undergo retro-conjugate addition4-8. This subsequently leads to undesirable transfer of the 
attached cargo onto blood thiols, particularly human serum albumin, thus resulting in off-target 
delivery. Herein we report the use of pyridazinediones9, 10 to functionalise the native solvent 
accessible interstrand disulfide bonds in trastuzumab to yield validated serum stable 
antibody conjugates with exactly 4 pyridazinediones  per full antibody. 
 We have previously shown that the application of re-bridging technologies in order to conjugate to 
interchain disulfide bridges is a powerful tool for circumventing many of the challenges associated 
with porphyrin ADCs,11, 12 allowing for targeted photocytotoxicity, while maintaining precise loading 
ratios and binding affinity. However, this technology was primarily designed for the generation of 
highly cytotoxic ADCs, for which the EC50 of the toxic payload is in the nanomolar range, or lower. 
In such ADCs, the generated drug-to-antibody ratio (DAR) of ca. 4 allows for excellent potency, with 
higher loading causing aggregation and rapid clearance in vivo due to the lipophilic nature of the drug. 
In contrast, the EC50 of porphyrins for PDT is significantly higher (typically in the micromolar 
range).13 As a result, porphyrin ADCs would benefit from the development of technologies which 
permit higher loading ratios, but which also overcome the inherent problems of direct lysine or 
cysteine conjugation (see above).  
Multiple loading strategies incorporating branched dendron units have previous been exploited within 
ADCs, usually in combination with enzymatic coupling strategies to obtain a DAR of 4-8.14 While use 
of multi-photosensitizer structures for PDT has also been demonstrated,15, 16 in contrast, the 
application of dendron technology for targeted PDT has been attempted only once previously.17 While 
the synthesized structures retained desirable photophysical characteristics, the harsh coupling 
conditions were applied only to highly hydrophobic porphyrins, and bioconjugation was not 
attempted.  
To this end, we have developed a range of dendron structures bearing 2-4 alkyne functionalities. 
These can undergo the copper-catalysed azide-alkyne cycloaddition (CuAAC) reaction with azide-
functionalised porphyrins, allowing mild attachment of water-soluble porphyrins in near-quantitative 
yields.18 The photophysical potential of these structures as therapeutic payloads was evaluated, and 
bioconjugation and biological evaluation of the lead structure was demonstrated. This represents the 
first example of a homogenous re-bridging bioconjugation technology, which permits increased 
payload DAR of up to 16 on a native antibody.  
Results and Discussion  
Initially, synthesis of a range of aryl ether dendrons 1-3 was carried out (Fig. 1), bearing 2-4 alkyne 
functional groups and a spacer chain bearing a protected amine group. For photophysical evaluation a 
short triethylene glycol spacer was used, engendering moderate hydrophilicity without the prohibitive 
cost of longer PEG chains. Synthesis of all intermediates was carried out using a literature method19, 
with the final addition of the triethylene glycol spacer carried out via peptide coupling to obtain the 
products in good yields.  
 
Figure 1. Structures of aryl ether dendrons 1-3. While 1 and 2 are single generation dendrons with 2 and 3 alkyne functionalities respectively, 3 is a second 
generation dendron with 4 alkyne functionalities.  
 
 
 
 
 
 
Porphyrins 4 and 5 have previously demonstrated excellent photocytotoxicity when attached to 
antibodies (Fig 2).12 Thus, their potential for porphyrin–dendron generation was explored and 
conjugation of both 4 and 5 on dendrons 1-3 was attempted via CuAAC reaction, with mild 
microwave heating employed in each case.  
Figure 2. Structures of hydrophilic porphyrins 4 and 5  
 
Reaction with dendron 1 proceeded well, with both porphyrins 4 and 5 rapidly reaching completion 
and requiring only simple workup without chromatographic purification, to produce products 6 and 7 
(Fig. 3) in excellent yield and purity. In contrast, the conjugation between porphyrin 4 and both 
dendrons 2 and 3 proceeded poorly. After 1 hour, HPLC analysis of the crude mixture showed 
consumption of the starting dendron, and formation of a single product, however NMR analysis 
revealed the formation of a product with one fewer porphyrin attached than expected (2 and 3 
respectively). Reaction intensification, including extended reaction times, addition of an excess of 
porphyrin, and heating to 60°C showed no appreciable formation of the desired product in either case. 
 
 
 
 
Figure 3. Synthetic scheme for dendrons 6 and 7. i, porphyrin (4 or 5), CuSO4, NaAsc, Tris(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA), 40°C, MW. 
 
In contrast, reactions between porphyrin 5 and dendrons 2 and 3 proceeded rapidly to completion, 
with NMR analysis confirming the attachment of 3 and 4 porphyrins respectively (see ESI). The 
successful synthesis of 8 and 9 (Fig. 4) can therefore be attributed to reduced steric hindrance as a 
result of the flexible triethylene glycol spacer chain on porphyrin 5, allowing more facile attachment 
of more than two porphyrin in the sterically hindered structure.  
 
Figure 4.. Synthetic scheme for dendrons 8 and 9. i, 5, CuSO4, NaAsc, TBTA, 40°C, MW. 
 
  
Following synthesis of structures 6-9, analysis of their photophysical properties was carried out. The close 
physical proximity of the porphyrins to one another and also to the central dendritic skeleton has the potential to 
lead to quenching of both the triplet excited state and generation of therapeutic singlet oxygen. As a result, both 
UV absorption of the principal Soret band, and singlet oxygen quantum yield (ΦΔ) for all porphyrins were 
evaluated, in comparison to control porphyrins 10 and 11 (Fig. 5) which were pre-reacted with propargyl amine 
to remove the reactive azide group. The UV-absorption of the Soret band was then divided by that of the 
relevant control porphyrin to obtain a UV absorption ratio for each porphyrin-dendron structure. In a perfect 
system, each porphyrin would retain identical photophysical characteristics in comparison to the control 
porphyrin, and thus the UV absorption ratio would be equivalent to that of the stoichiometry. 
 
 
Figure 5. Structures of control porphyrins 10 and 11. 
  
The most significant difference in UV-visible absorption was observed for 6 (Table 1), with the 
reduction observed (ca. 30%) being unsurprising since this was the only structure to employ the more 
sterically-hindered porphyrin 4. A modest reduction (ca. 10%) was also observed for 8, which can be 
attributed the larger number of porphyrins in comparison to 7. In comparison to 9, while the number 
of porphyrins is smaller, the three porphyrins are arranged on the single generation dendron 2 rather 
than the second generation dendron 3. A lack of this second layer of branching increases the 
proximity of the three porphyrins of 8, and thus quenching is higher. In contrast to the other 
structures, 9 actually showed a small increase in UV absorption in comparison to the same 
stoichiometric quantity of the parent porphyrin. The reason for this effect is not known, however it is 
possible that the rigid structure of this second generation dendron allows for regular spacing between 
porphyrins to be maintained more easily than between free porphyrins in solution (which may have a 
tendency towards aggregation), allowing improved absorption characteristics. 
 
Table 1. Photophysical data for structures 6-11.  
Structure Stoichiometry[a] ΦΔ[b] UV absorption ratio[c] ΦΔ,  generation potential 
[d] 
10 1 0.47 1 0.47 
11 1 0.86 1 0.86 
6 2 0.21 1.41 0.29 
7 2 0.27 1.98 0.53 
8 3 0.28 2.68 0.75 
9 4 0.28 4.30 1.20 
[a] As determined by NMR [b] Normalised ΦΔ (in D2O) [c] Ratio of total UV absorption (in H2O) of structure to the 
absorption of the single porphyrin analogue. In a perfect system this would be equal to the stoichiometry. [d] Calculation 
of the singlet oxygen generation potential of the entire porphyrin-dendron system, calculated as a function of normalised 
ΦΔ and UV absorption ratio. 
In general, it can be seen that the ΦΔ values are highest for the control porphyrins 10 and 11. The 
reduced ΦΔ of 10 in comparison to 11 suggests that the proximity of the triazole ring also reduces 
the quantum yield, possibly as a result of direct quenching of the porphyrin. While all synthesised 
porphyrin-dendron conjugates demonstrated reduced ΦΔ in comparison to the control porphyrins, 
a surprising lack of variation between the conjugates was observed. A minor change was again 
observed with the use of the PEG spacer, with an increase in ΦΔ between 6 and 7. However, no 
significant difference in the ΦΔ between 7, 8 and 9 was observed, suggesting that the quenching 
in these systems is not significantly increased by the addition of subsequent porphyrins.  
While it is evident that the porphyrin-dendron conjugates produce less singlet oxygen per 
quanta of absorbed light, their increased absorption of light in comparison to single 
porphyrins is sufficient to overcome this in a therapeutic context. For this reason, the singlet 
oxygen generation potential of each structure was calculated by multiplying the absorption 
ratio by ΦΔ in order to accurately reflect the hypothetical total production of singlet oxygen of 
the entire porphyrin-dendron structure in an abundance of light, such as in clinical use. 
Comparison of these values demonstrates that the overall therapeutic efficacy of the structures 
increases with increasing porphyrin loading. Despite this increase, only 9 has a singlet oxygen 
generation potential in excess of its parent porphyrin 11.  
For this reason, 9 was selected as the most promising candidate for development into a high-
potency therapeutic. It was envisaged that replacing the triethylene glycol spacer with a PEG6 
chain would increase hydrophilicity and facilitate bioconjugation. Thus, synthesis of an analogue 
of 3 with a longer PEG chain was carried out. Synthesis of 12 (Fig. 6) was carried out via the 
same peptide coupling methodology as 3 to afford 12 in moderate yield.  
Figure 6. Synthetic scheme for structures 12-14. i, 5, CuSO4, NaAsc, TBTA, 40°C, MW, ii, TFA, 40°C. iii, imidazole-1-sulfonyl azide hydrogen sulfate, 
copper (II) sulfate pentahydrate, 40°C. 
 
 
Similarly, the synthesis of 13 was carried out under identical conditions to 9, with microwave 
irradiation at 40°C yielding the desired product without chromotographic purification, followed by 
immediate deprotection of the Boc protecting group. Finally, to allow for bioconjugation under 
previously optimised conditions, azide functionalisation of the amine focal point was carried out.7 14 
was prepared utilising a diazotransfer reagent (imidazole-1-sulfonyl azide) previously shown to be 
compatible with porphyrins.20 The reaction was monitored by HPLC, and 14 was obtained in good 
yield after workup. 
With 14 in hand, bioconjugation to the HER2-targeting antibody trastuzumab® was explored. As well 
as demonstrating clinical relevance as both a therapeutic antibody and in the clinical ADC Kadcyla®, 
trastuzumab® also acts as an excellent model for bioconjugation to other IgG1 antibodies, 
demonstrating the versatility of this bioconjugation method for new and existing disease targets. 
Initially, functional re-bridging on the four solvent-accessible disulfide bridges was performed 
through concomitant reduction with TCEP and the strained alkyne functionalised pyridazinedione 15 
(Fig. 7) for 16 hrs at 4 °C. UV analysis confirmed a DAR of ca 4.  
Figure 7. Schematic representation of the functional rebridging of trastuzumab with pyridazinedione 15. 
 
Subsequent strain-promoted (SPAAC) attachment of 14 was carried out at 21°C for 6 hours, followed 
by gel filtration to remove excess reagents (Fig. 8). UV analysis was performed on conjugate 18, to 
determine an average DAR of 15.4 porphyrins per antibody, close to the theoretical maximum of 16 
across the 4 interchain disulfide bridges. Further analysis by SDS-PAGE demonstrates complete re-
bridging of the bioconjugate, with no partial re-bridging or unconjugated antibody fragments at lower 
molecular weight observed. 
Figure 8. Schematic representation of strain-promoted click conjugation of the azide-functionalised dendron 14 onto funtionalised bioconjugate 17. 
 
Following successful bioconjugation, we next appraised the efficacy of the synthesised ADC in vitro 
on cell lines which overexpress (BT-474) and express native levels of HER2 receptor (MDA-MB-
468), using unmodified trastuzumab® as a control.  (Fig. 9) As in our previous work,7 in vitro 
experiments were carried out utilising broad spectrum illumination (20 J cm-2) rather than red / near 
IR light. This allows a more accurate reflection of the potency of the conjugate in a clinical setting, 
where the use of biomedical lasers compensates for the reduced absorption of the porphyrins in the 
red region through light fluences which are orders of magnitude greater.  
Under these conditions, conjugate 18 demonstrated an impressive photocytotoxic effect against the 
HER2 overexpressing cells, with a nanomolar LD90 value, while at the same concentration leaving 
HER2- cells unaffected (Fig. 9). In both cases, the control native trastuzumab displayed no 
cytotoxicity at these concentrations. In addition, 18 displayed no dark toxicity in both cell lines even 
at the highest concentration used (1 µM) (see ESI).  
Figure 9. Graph demonstrating cell survival of BT-474 and MDA-MB-468 cell lines following incubation with either conjugate 18 or unmodified trastuzumab® 
control at the LD90 dose, and irradiation (20 J cm-2) (Full cytotoxicity data is available in ESI).  
 
In conclusion, we have demonstrated the first synthesis of a range of click-enabled porphyrin-dendron 
multipliers for bioconjugation applications, with a mild and facile synthetic procedure. Following 
evaluation of the photophysical characteristics of these structures, we selected a lead candidate and 
optimised bioconjugation using the HER2-targeting clinical antibody trastuzumab®. Subsequent in 
vitro biological evaluation confirmed the selectivity and potency of this porphyrin 
photoimmunoconjugate, with a remarkable nanomolar LD90 value on HER2 overexpressing cells, and 
no observable effect on cells that express native HER2 levels, nor dark cytotoxicity, at the same 
concentration. The clear lack of effect from the trastuzumab® control at the LD90 value, and in the 
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absence of light, shows cytotoxic action is promoted only by light activation of the photosensitisers. 
The large differential seen between HER2 overexpressing cells, and those with native HER2 levels 
(Fig. 9) confirms receptor binding is unaffected by conjugation of the porphyrin dendron. Clearly, 
trastuzumab® is well known to elicit an anticancer effect on HER2 positive tumours, and is routinely 
used in the clinic. The results presented here offer an exciting potential for augmenting the therapeutic 
effects of trastuzumab® by controlled conjugation of photosensitiser dendrons to this antibody. 
 
 
Materials and methods 
General peptide coupling method: To a stirred solution of dendron acid (1.1 mmol) in 
dichloromethane (100 mL) was added tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate (0.272 
g, 1.1 mmol) in dichloromethane (50 mL). DIPEA (0.35 mL, 2.5 mmol) was added, followed by 
addition of PyBOP (0.572 g, 1.1 mmol), and the mixture was stirred at rt overnight. The solvent was 
removed under reduced pressure and the crude material purified by column chromatography (silica, 
5% MeOH:DCM) to yield the product as a colourless oil. 
General microwave click method: To a 10 mL microwave tube was added zinc 5-[4-azidophenyl]-
10,15,20-tri-(N-methyl-4-pyridinium)porphyrin trichloride (2-4 equivalents) and dendron 1-3 (19 mg, 
0.022 mmol) in tBuOH:water (1:1, 8 mL). Copper (II) sulfate pentahydrate (5 mg), sodium ascorbate 
(5 mg), and TBTA (1 mg) was added, and the mixture heated to 40°C by MW (75W, max pressure 
100 bar, max stirring) for 1 hour. The mixture was concentrated under reduced pressure, and 
ammonium hexafluorophosphate added to the mixture. The resulting solution was filtered and the 
precipitate re-dissolved in acetone. Tetrabutylammonium chloride was added, and the resulting 
solution filtered. The product was precipitated from diethyl ether over MeOH to yield the product as a 
green solid. 
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